Led or contributed to 2G BIOPIC, BABET-REAL5, WASTE2FUELS, Zelcor, and ConCO2rde — all focused on converting biomass or CO2 into fuels and valuable chemicals.
INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE
French engineering school with strong bioprocess, enzyme engineering, nanoparticle, and aeronautics labs active across 32 H2020 projects.
Their core work
INSA Toulouse is one of France's top engineering schools (Grandes Écoles), with deep laboratory expertise in biotechnology, chemical engineering, and materials science. Their H2020 work centers on converting biomass into fuels and chemicals (biorefineries), developing biopesticides and biocontrol agents, and engineering advanced nanoparticle systems for medical imaging and drug delivery. They also contribute aeronautics and flow control research through Clean Sky partnerships, and provide microfluidics and catalysis capabilities to multi-partner European consortia.
What they specialise in
Coordinated CaTSYS and EvoXUL on carbohydrate-active enzymes, participated in IBISBA 1.0 and PREP-IBISBA synthetic biology infrastructure, and METAFLUIDICS for metagenomic screening.
Coordinated IPM-4-Citrus on Bacillus thuringiensis biopesticide scale-up and formulation, and contributed to PPILOW on sustainable livestock systems.
Participated in SWIMMOT (magneto-plasmonic contrast agents), HeatNMof (metal-organic frameworks for drug delivery), and MONACAT (nanoparticle catalysis).
Contributed to REG GAM 2018, GAM-2020-REG regional aircraft programs, RODEO orbital drilling, and PERSEUS pulsed jet actuators for turbulent flow separation control.
Participated in MIGRATE (miniaturized gas flow), MACAO (microfluidic air quality sensors), and HoliFAB (microfluidic MEMS prototyping).
How they've shifted over time
In the early H2020 period (2014–2018), INSA Toulouse focused heavily on second-generation biofuels and biorefinery processes (2G BIOPIC, WASTE2FUELS, BABET-REAL5) alongside enzyme and microbiome research (CaTSYS, METAFLUIDICS). From 2019 onward, their work shifted toward synthetic biology, CO2 bioconversion (ConCO2rde), nanoparticle-based medical technologies (SWIMMOT, HeatNMof), and co-creation approaches in sustainable agriculture (PPILOW). The trend shows a move from converting plant biomass into fuels toward higher-value applications — engineered biology, medical nanomaterials, and circular carbon systems.
INSA Toulouse is pivoting from biomass-to-fuel research toward synthetic biology platforms and nanoparticle-based biomedical applications, making them an increasingly relevant partner for health-tech and bio-manufacturing consortia.
How they like to work
INSA Toulouse predominantly joins projects as a participant or third party (28 of 32 projects), contributing specialized lab capabilities rather than leading large consortia. Their 4 coordinated projects are smaller-budget, research-focused efforts (CaTSYS, IPM-4-Citrus, SOLFORPLAS, EvoXUL), suggesting they lead where they have deep domain ownership. With 447 unique partners across 37 countries, they are a well-connected hub — easy to integrate into new consortia and experienced in navigating large multi-partner projects.
INSA Toulouse has collaborated with 447 distinct partners across 37 countries, reflecting broad European reach with particularly strong ties to France's aerospace and biotech ecosystems. Their Clean Sky and EUROfusion participation connects them to major industrial players in aviation and energy.
What sets them apart
INSA Toulouse bridges biotechnology and engineering in a way few academic partners can — they combine enzyme discovery, bioprocess scale-up, and nanoparticle design under one roof. Their Toulouse location places them at the heart of France's aerospace cluster (Airbus, Clean Sky) while their biology labs connect to Europe's industrial biotech infrastructure (IBISBA). For consortium builders, they offer rare versatility: the same institution can contribute biorefinery expertise, nanomaterial synthesis, and aeronautical testing.
Highlights from their portfolio
- SWIMMOTTheir largest single EC contribution (EUR 842K), developing switchable magneto-plasmonic contrast agents — signals a major institutional bet on biomedical nanotechnology.
- IPM-4-CitrusCoordinated project taking Bacillus thuringiensis biopesticides from lab to market, including scale-up, formulation, field trials, and spin-off planning — a rare full-pipeline effort.
- ConCO2rdeLarge training network (EUR 824K) on CO2 bioconversion via synthetic biology, positioning INSA at the intersection of carbon capture and industrial biotechnology.